- Home
- GENC vs LRMR Comparison
GENC vs LRMR Comparison
Compare GENC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- LRMR
- Stock Information
- Founded
- GENC 1894
- LRMR N/A
- Country
- GENC United States
- LRMR United States
- Employees
- GENC 317
- LRMR N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- LRMR Health Care
- Exchange
- GENC Nasdaq
- LRMR Nasdaq
- Market Cap
- GENC 190.6M
- LRMR 183.8M
- IPO Year
- GENC N/A
- LRMR N/A
- Fundamental
- Price
- GENC $13.31
- LRMR $2.12
- Analyst Decision
- GENC
- LRMR Strong Buy
- Analyst Count
- GENC 0
- LRMR 9
- Target Price
- GENC N/A
- LRMR $19.00
- AVG Volume (30 Days)
- GENC 22.7K
- LRMR 1.4M
- Earning Date
- GENC 05-16-2025
- LRMR 04-30-2025
- Dividend Yield
- GENC N/A
- LRMR N/A
- EPS Growth
- GENC 35.02
- LRMR N/A
- EPS
- GENC 1.11
- LRMR N/A
- Revenue
- GENC $113,116,000.00
- LRMR N/A
- Revenue This Year
- GENC N/A
- LRMR N/A
- Revenue Next Year
- GENC N/A
- LRMR N/A
- P/E Ratio
- GENC $11.87
- LRMR N/A
- Revenue Growth
- GENC 5.44
- LRMR N/A
- 52 Week Low
- GENC $10.80
- LRMR $1.61
- 52 Week High
- GENC $24.88
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- GENC 60.04
- LRMR 44.72
- Support Level
- GENC $12.00
- LRMR $2.03
- Resistance Level
- GENC $13.59
- LRMR $2.33
- Average True Range (ATR)
- GENC 0.61
- LRMR 0.30
- MACD
- GENC 0.15
- LRMR -0.01
- Stochastic Oscillator
- GENC 82.69
- LRMR 11.21
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.